Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

ontrol of capillary, venous, and

arteriolar bleeding by pressure, ligature and conventional procedures

is ineffective or impractical.

-- The launch of the company's V-Link Luer-activated device (LAD) with

VitalShield protective coating, the first needleless IV connector

containing an antimicrobial coating. The protective coating has been

shown to kill on average 99.9 percent of specific common pathogens

(infection-causing microorganisms) within the device that are known to

cause catheter-related blood stream infections, including the highly

treatment-resistant bacteria called methicillin-resistant

Staphylococcus aureus, or MRSA.

-- The announcement of preliminary results of a Phase I/II clinical trial,

in which subcutaneous infusion (under the skin) of GAMMAGARD LIQUID

[Immune Globulin Intravenous (Human)] (IGIV) with Enhanze(TM)

Technology enabled administration of a full monthly dose via a single

site to patients with primary immunodeficiency (PID).

Second Quarter and Full-Year 2008 Outlook

Baxter also announced today that it is raising its earnings outlook for full-year 2008. The company continues to expect sales growth, excluding the impact of foreign exchange, of 5 to 6 percent. Excluding Transfusion Therapies from both 2007 and 2008 and excluding foreign exchange, the company expects sales growth of approximately 6 to 7 percent. Baxter now expects to achieve earnings per diluted share of $3.18 to $3.24, before any special items, and cash flow from operations of approximately $2.6 billion. Previously, the company had provided earnings guidance of $3.10 to $3.18 per diluted share, excluding special items, and expected to generate cash flow from operations of more than $2.5 billion.

For the second quarter of 2008, Baxter expects sales growth of 4 to 5 percent, excluding the impact of foreign exchange, and earnings
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), ... and Mr. David Pendarvis to its board of ... ,, Kenneth F. Buechler, Ph.D., was president, chief ... 1988 to 1994, Dr. Buechler was Biosite,s director ... was a senior research scientist for the diagnostics ...
(Date:12/16/2009)... BioSciences, LLC introduces HSP-A Soy Peptone. HSP A has been ... , ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ... introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. ... proven to improve growth rates and yields. HSP-A has been ...
(Date:12/15/2009)... 15 Repligen Corporation (Nasdaq: RGEN ... $731,000 in research funding to support the ongoing ... the Muscular Dystrophy Association (MDA). This grant ... testing and GMP manufacture of a drug candidate ... MDA not only provides important funding for Repligen,s ...
(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...
Breaking Biology Technology:Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3
... One Corporation,(Pink Sheets: MNCN), a biological solutions company that ... the agricultural and consumer,market, announced today that it has ... Investor. , Mach One issued ... first production facility in Wisconsin. The Original Note ...
... CITY, Calif., Jan. 22 Abaxis, Inc. (Nasdaq: ... systems, has scheduled a conference call to discuss its financial ... December 31, 2008. The call will be at 4:15 p.m. ... or (706) 643-0580 to access the conference call, or can ...
... METTLER TOLEDO FBRM® provides an information-rich method for tracking the number ... process. In any given particle system, there are specific and ... This three part complimentary webinar series will provide you with ... data analysis. , ...
Other Biology Technology:Mach One Completes Note Exchange 2Abaxis to Report Third Quarter Fiscal 2009 Financial Results Thursday, January 29, 2009 2Maximize Data Analysis with METTLER TOLEDO FBRM 2
(Date:12/16/2009)... superstitions and rituals can help them get psyched up ... drugs (NSAIDs), which many athletes gobble down before and ... good. , "These agents are treatments for the symptoms ... Warden, whose research at Indiana University focuses on musculoskeletal ... to exercise or train at a certain level, but ...
(Date:12/16/2009)... NEW YORK, Dec. 1 iQor, a global ... in the 2009 InfoWorld 100 Awards Top ... system, TeQ21. This was the first submission for iQor. ... prestigious list of companies," said Vikas Kapoor, president and ... we do business, allowing us to work faster, smarter ...
(Date:12/16/2009)... 7 IgeaCare Solutions Inc. is pleased ... the healthcare communications company previously operating as IgeaCare ... now move forward under new leadership and funding. ... Rochon to the position of Chief Executive Officer. ... on providing a superior servicing and support model; ...
Breaking Biology News(10 mins):NSAIDs: Take 'em early and often when competing? Think again 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Verathon Introduces the GlideScope 28R 29 Cobalt Advanced Video Laryngoscope 28AVL 29 3B New Digital Technology Facilitates Quick Intubations 5517 1Verathon Introduces the GlideScope 28R 29 Cobalt Advanced Video Laryngoscope 28AVL 29 3B New Digital Technology Facilitates Quick Intubations 5517 2American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver 5514 1American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver 5514 2American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver 5514 3American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver 5514 4Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over Allotment Option 5511 1Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over Allotment Option 5511 2
... (April 21, 2008) The technique lizards use to grab ... Ohio University. , A research team led by doctoral ... they walked or ran in order to understand how their ... National Science Foundation, was featured in the April 1 edition ...
... Virginia Bioinformatics Institute (VBI) at Virginia Tech and their ... family of virulence proteins that play an important role ... pathogen Phytophthora sojae. , VBI Professor Brett Tyler ... from Virginia Techs Department of Plant Pathology, Physiology and ...
... FOR IMMEDIATE RELEASE , Gel-like material shows ... , Researchers in Texas report development of a gel-like material ... can be taken in a pill by mouth, rather than ... issue of ACS Biomacromolecules, a monthly journal. , In the ...
Other Biology News:Lizard hunting styles impact ability to walk, run 2American Chemical Society's Weekly PressPac -- April 16, 2008 2American Chemical Society's Weekly PressPac -- April 16, 2008 3American Chemical Society's Weekly PressPac -- April 16, 2008 4American Chemical Society's Weekly PressPac -- April 16, 2008 5American Chemical Society's Weekly PressPac -- April 16, 2008 6American Chemical Society's Weekly PressPac -- April 16, 2008 7American Chemical Society's Weekly PressPac -- April 16, 2008 8
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
... products perform optimally when used ... MagCellect Magnet. To accommodate different ... boron permanent magnet holds either ... test tubes or two 15 ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Biology Products: